Clinical trial

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

NCT01313273

Study summary

ClinicalTrials.gov

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Lanreotide, non steroidal anti androgens and LHRH-a Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Non steroidal anti androgens and LHRH-a Find medicine records · Find other trials using this name

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2011-06-01

PhasePHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Interventions

Lanreotide, non steroidal anti androgens and LHRH-aDRUG

Non steroidal anti androgens and LHRH-aDRUG

Sponsors & collaborators

Ipsenlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01313273 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.